219 related articles for article (PubMed ID: 33743541)
1. A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Sterling RK; King WC; Khalili M; Chung RT; Sulkowski M; Jain MK; Lisker-Melman M; Ghany MG; Wong DK; Hinerman AS; Bhan AK; Wahed AS; Kleiner DE;
Hepatology; 2021 Sep; 74(3):1174-1189. PubMed ID: 33743541
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection.
Chung RT; King WC; Ghany MG; Lisker-Melman M; Hinerman AS; Khalili M; Sulkowski M; Jain MK; Choi EK; Nalesnik MA; Bhan AK; Cloherty G; Wong DK; Sterling RK;
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):125-135.e8. PubMed ID: 34973459
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.
Sterling RK; Wahed AS; King WC; Kleiner DE; Khalili M; Sulkowski M; Chung RT; Jain MK; Lisker-Melman M; Wong DK; Ghany MG;
Am J Gastroenterol; 2019 May; 114(5):746-757. PubMed ID: 30410040
[TBL] [Abstract][Full Text] [Related]
4. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
Lok AS; Perrillo R; Lalama CM; Fried MW; Belle SH; Ghany MG; Khalili M; Fontana RJ; Sterling RK; Terrault N; Feld JJ; Di Bisceglie AM; Lau DTY; Hassan M; Janssen HLA;
Hepatology; 2021 Jun; 73(6):2124-2140. PubMed ID: 32936969
[TBL] [Abstract][Full Text] [Related]
5. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
6. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
7. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM;
Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992
[TBL] [Abstract][Full Text] [Related]
8. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
9. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
10. Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Bzowej NH; Tran TT; Li R; Belle SH; Smith CI; Khalili M; Chung R; Tsai N; Terrault N;
Am J Gastroenterol; 2019 Aug; 114(8):1283-1291. PubMed ID: 31082876
[TBL] [Abstract][Full Text] [Related]
11. Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
Peters L; Mocroft A; Grint D; Moreno S; Calmy A; Jevtovic D; Sambatakou H; Lacombe K; De Wit S; Rockstroh J; Smidt J; Karpov I; Grzeszczuk A; Haziosmanovic V; Gottfredsson M; Radoi R; Kuzovatova E; Orkin C; Ridolfo AL; Zapirain J; Lundgren J
Antivir Ther; 2018; 23(5):405-413. PubMed ID: 29303483
[TBL] [Abstract][Full Text] [Related]
12. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
13. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
Pradeep Kumar S; Medhi S; Asim M; Das BC; Gondal R; Kar P
Indian J Med Res; 2011 Jan; 133(1):50-6. PubMed ID: 21321419
[TBL] [Abstract][Full Text] [Related]
16. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
17. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
J Antimicrob Chemother; 2021 Oct; 76(11):3009-3019. PubMed ID: 34458919
[TBL] [Abstract][Full Text] [Related]
18. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
19. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
Coffin CS; Osiowy C; Myers RP; Gill MJ
J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
[TBL] [Abstract][Full Text] [Related]
20. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
